


PHARMACEUTICAL 2017

## Regen BioPharma Inc Rank 310 of 313







## Regen BioPharma Inc Rank 310 of 313

The relative strengths and weaknesses of Regen BioPharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen BioPharma Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 915% points. The greatest weakness of Regen BioPharma Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 4,344% points.

The company's Economic Capital Ratio, given in the ranking table, is -5,240%, being 4,824% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	207
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	799
Liabilities, Non-Current	0
Other Assets	112
Other Compr. Net Income	0
Other Expenses	722
Other Liabilities	107
Other Net Income	-4,794
Property and Equipment	0
Research and Development	671
Revenues	100
Selling, General and Administrative Expense	1,664

Output Variable	Value in 1000 USD
Assets	319
Liabilities	906
Expenses	3,057
Stockholders Equity	-587
Net Income	-7,751
Comprehensive Net Income	-7,751
Economic Capital Ratio	-5,240%

